Critical Contrast: Longeveron (NASDAQ:LGVN) vs. ULURU (OTCMKTS:ULUR)

Longeveron (NASDAQ:LGVN) and ULURU (OTCMKTS:ULUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.

Insider and Institutional Ownership

10.0% of Longeveron shares are owned by institutional investors. 19.1% of Longeveron shares are owned by insiders. Comparatively, 1.1% of ULURU shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Longeveron has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, ULURU has a beta of -3.13, suggesting that its stock price is 413% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Longeveron and ULURU, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	0	0	2	0	3.00
ULURU	0	0	0	0	N/A

Longeveron presently has a consensus target price of $8.00, suggesting a potential upside of 346.93%.

Profitability

This table compares Longeveron and ULURU’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,513.83%	-237.57%	-140.97%
ULURU	N/A	N/A	N/A

Valuation and Earnings

This table compares Longeveron and ULURU”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.23 million	9.25	-$21.41 million	($9.61)	-0.19
ULURU	N/A	N/A	N/A	N/A	N/A

ULURU has lower revenue, but higher earnings than Longeveron.

Summary

Longeveron beats ULURU on 5 of the 8 factors compared between the two stocks.

About Longeveron

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

About ULURU

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.